ArticleData in brief2025
Dataset on potential biochemical activities of Cylo phe-Ala-Asp-Gly-based compounds as Caspase 1 inhibitor.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Caspase-1 inhibition: mechanistic insights and comprehensive review of reported inhibitors to date.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, seven Cylo phe-Ala-Asp-Gly-based Compounds were optimized using Spartan'14 software. Series of software used in this work were Spartan 14, molecular operating environment (MOE), padel, ADMET. The optimized compounds were docked against human Caspase 1 (6F6R) so as to observe their inhibiting ability. The calculated descriptors for individual compounds were reported and described. Also, the docked compound 2 (2-((2S,8S,11S)-11-([1,1'-biphenyl]-4-ylmethyl)-8-benzyl-3,6,9,12-tetraoxo-1,4,7,10-tetraazacyclododecan-2-yl) acetic acid) proved to be more efficient in inhibiting human caspase 1 than other compounds under investigation. The pharmacokinetic evaluation of compound with highest binding affinity and reference compound were executed and reported
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.